SIETES :: 93020 citas

Resultados de la búsqueda por ZOLPIDEM REFINAR BÚSQUEDA

21.

Booth JN, Behring M, Cantor RS, Colantonio LD, Davidson S, Donnelly JP, Johnson E, Jordan K, Singleton C, Xie F, McGwin G. Zolpidem use and motor vehicle collisions in older drivers . Sleep Medicine 2015:29 de diciembre. [Ref.ID 99807]

22.

Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. Association between benzodiazepine use and exacerbation and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf 2015;24:793-802. [Ref.ID 99471]

23.

Anónimo. Drugs for insomnia. Med Lett Drugs Ther 2015;57:95-8. [Ref.ID 99452]

24.

Hansen RN, Boudreau DM, Ebel BE, Grossman DC, Sullivan SD. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health 2015;105:e64-69. [Ref.ID 99174]

25.

Anónimo. Seguridad de medicamentos: señales y alertas generadas en 2013-2014. Infac: Información Farmacoterapéutica de la Comarca 2015;23:16-26. [Ref.ID 99145]

26.

Azparren Andía A, García Romero I. Estrategias para la deprescripción de benzodiazepinas. Boletín de Información Farmacoterapéutica de Navarra 2014;22:1-12. [Ref.ID 98237]

27.

Anónimo. Benzodiacepinas: riesgos y estrategias para su retirada. Boletín Terapéutico Andaluz 2014;29:10-6. [Ref.ID 98202]

28.

Hampton LM, Daubresse M, Chang HY, Alexander C, Budnitz DS. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry 2014;71:1006-14. [Ref.ID 97739]

29.

Madurga M. Zolpidem: riesgo de somnolencia al día siguiente. PAM 2014;38:325-6. [Ref.ID 97721]

30.

Anónimo. Prescriptions for anxiolytics and hypnotics and risk of death. Eyes on Evidence 2014:junio. [Ref.ID 97691]

31.

Anónimo. Study: sleep aid use in US on the rise. DIA Daily 2014:21 de febrero. [Ref.ID 97515]

32.

Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014;348:g1996. [Ref.ID 97297]

33.

Puustinen J, Lähteenmäki R, Polo-Kantola P, Salo P, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL. Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. Eur J Clin Pharmacol 2014;70:319-29. [Ref.ID 97277]

34.

Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]

35.

Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Pivette J, Chaslerie A, Sébille V, Jolliet P. Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol 2013;69:1965-72. [Ref.ID 96504]

36.

Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment - Identifying persons at risk. N Engl J Med 2013;369:689-91. [Ref.ID 96014]

37.

Vicente Sánchez MP, Macías Saint-Gerons D, de la Fuente Honrubia C, González Bermejo D, Montero Corominas D, Catalá-López F. Evolución del uso de medicamentos ansiolíticos e hipnóticos en España durante el período 2000-2011. Rev Esp Salud Pública 2013;87:247-55. [Ref.ID 95641]

38.

Mitka M. Zolpidem-related surge in emergency department visits. JAMA 2013;309:2203. [Ref.ID 95599]

39.

Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med 2013;173:754-61. [Ref.ID 95423]

40.

Anónimo. Emergency department visits for adverse reactions involving the insomnia medication zolpidem. SAHMSA. The DAWN Report 2013:1 de mayo. [Ref.ID 95316]